Abstract

Hyperinsulinaemia, a pre-clinical condition which is considered to predict insulin resistance and metabolic syndrome, has not been sufficiently investigated in bipolar disorder, despite evidence to suggest that bipolar patients are at risk of developing insulin resistance. This study was set out to determine the alteration in fasting insulin levels and evaluate the factors associated with hyperinsulinaemia during manic episodes. Measurements were taken of the fasting plasma insulin and leptin levels, as well as the body mass index (BMI), amongst 42 physically healthy bipolar I manic (DSM-IV) patients aged ≤ 45 with Young Mania Rating Scale (YMRS) scores of ≥ 26. These were then compared with their values in subsequent remission (YMRS ≤ 12). A total of 14 patients (33.3%) in acute mania and 30 patients (71.4%) in subsequent remission met the Taiwanese criteria for hyperinsulinaemia of ≥ 8.7 μIU/ml for men, and ≥ 11.3 μIU/ml for women. Multiple analyses were then undertaken, without correction, as the exploratory analyses. The measurement, by logistic regression, of the use of propranolol in remission (odds ratio [OR] = 10.04, 95% confidence interval [95% CI] = 1.03-97.96) and the increase in BMI (OR = 1.35, 95% CI = 1.01-1.80) were found to have independent associations with hyperinsulinaemia in subsequent remission. Our results suggest that medicated bipolar manic patients are vulnerable to hyperinsulinaemia in early remission, particularly those gaining bodyweight or those using β-adrenoceptor antagonist (beta-blockers), irrespective of the types of mood stabilizers or antipsychotics used.

Original languageEnglish
Pages (from-to)1038-1043
Number of pages6
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume31
Issue number5
DOIs
Publication statusPublished - Jun 30 2007

Fingerprint

Hyperinsulinism
Adrenergic Receptors
Bipolar Disorder
Insulin Resistance
Fasting
Body Mass Index
Odds Ratio
Confidence Intervals
Insulin
Leptin
Propranolol
Diagnostic and Statistical Manual of Mental Disorders
Antipsychotic Agents
Logistic Models

Keywords

  • Beta-blocker
  • Bipolar I disorder in Taiwan
  • Bodyweight gain
  • Hyperinsulinaemia
  • Insulin resistance
  • Manic episode

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

@article{2727b44a017f43de8a47392992e760ec,
title = "Hyperinsulinaemia associated with β-adrenoceptor antagonist in medicated bipolar patients during manic episode",
abstract = "Hyperinsulinaemia, a pre-clinical condition which is considered to predict insulin resistance and metabolic syndrome, has not been sufficiently investigated in bipolar disorder, despite evidence to suggest that bipolar patients are at risk of developing insulin resistance. This study was set out to determine the alteration in fasting insulin levels and evaluate the factors associated with hyperinsulinaemia during manic episodes. Measurements were taken of the fasting plasma insulin and leptin levels, as well as the body mass index (BMI), amongst 42 physically healthy bipolar I manic (DSM-IV) patients aged ≤ 45 with Young Mania Rating Scale (YMRS) scores of ≥ 26. These were then compared with their values in subsequent remission (YMRS ≤ 12). A total of 14 patients (33.3{\%}) in acute mania and 30 patients (71.4{\%}) in subsequent remission met the Taiwanese criteria for hyperinsulinaemia of ≥ 8.7 μIU/ml for men, and ≥ 11.3 μIU/ml for women. Multiple analyses were then undertaken, without correction, as the exploratory analyses. The measurement, by logistic regression, of the use of propranolol in remission (odds ratio [OR] = 10.04, 95{\%} confidence interval [95{\%} CI] = 1.03-97.96) and the increase in BMI (OR = 1.35, 95{\%} CI = 1.01-1.80) were found to have independent associations with hyperinsulinaemia in subsequent remission. Our results suggest that medicated bipolar manic patients are vulnerable to hyperinsulinaemia in early remission, particularly those gaining bodyweight or those using β-adrenoceptor antagonist (beta-blockers), irrespective of the types of mood stabilizers or antipsychotics used.",
keywords = "Beta-blocker, Bipolar I disorder in Taiwan, Bodyweight gain, Hyperinsulinaemia, Insulin resistance, Manic episode",
author = "Tsai, {Shang Ying} and Lee, {Hsin Chien} and Chen, {Chiao Chicy}",
year = "2007",
month = "6",
day = "30",
doi = "10.1016/j.pnpbp.2007.03.003",
language = "English",
volume = "31",
pages = "1038--1043",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Hyperinsulinaemia associated with β-adrenoceptor antagonist in medicated bipolar patients during manic episode

AU - Tsai, Shang Ying

AU - Lee, Hsin Chien

AU - Chen, Chiao Chicy

PY - 2007/6/30

Y1 - 2007/6/30

N2 - Hyperinsulinaemia, a pre-clinical condition which is considered to predict insulin resistance and metabolic syndrome, has not been sufficiently investigated in bipolar disorder, despite evidence to suggest that bipolar patients are at risk of developing insulin resistance. This study was set out to determine the alteration in fasting insulin levels and evaluate the factors associated with hyperinsulinaemia during manic episodes. Measurements were taken of the fasting plasma insulin and leptin levels, as well as the body mass index (BMI), amongst 42 physically healthy bipolar I manic (DSM-IV) patients aged ≤ 45 with Young Mania Rating Scale (YMRS) scores of ≥ 26. These were then compared with their values in subsequent remission (YMRS ≤ 12). A total of 14 patients (33.3%) in acute mania and 30 patients (71.4%) in subsequent remission met the Taiwanese criteria for hyperinsulinaemia of ≥ 8.7 μIU/ml for men, and ≥ 11.3 μIU/ml for women. Multiple analyses were then undertaken, without correction, as the exploratory analyses. The measurement, by logistic regression, of the use of propranolol in remission (odds ratio [OR] = 10.04, 95% confidence interval [95% CI] = 1.03-97.96) and the increase in BMI (OR = 1.35, 95% CI = 1.01-1.80) were found to have independent associations with hyperinsulinaemia in subsequent remission. Our results suggest that medicated bipolar manic patients are vulnerable to hyperinsulinaemia in early remission, particularly those gaining bodyweight or those using β-adrenoceptor antagonist (beta-blockers), irrespective of the types of mood stabilizers or antipsychotics used.

AB - Hyperinsulinaemia, a pre-clinical condition which is considered to predict insulin resistance and metabolic syndrome, has not been sufficiently investigated in bipolar disorder, despite evidence to suggest that bipolar patients are at risk of developing insulin resistance. This study was set out to determine the alteration in fasting insulin levels and evaluate the factors associated with hyperinsulinaemia during manic episodes. Measurements were taken of the fasting plasma insulin and leptin levels, as well as the body mass index (BMI), amongst 42 physically healthy bipolar I manic (DSM-IV) patients aged ≤ 45 with Young Mania Rating Scale (YMRS) scores of ≥ 26. These were then compared with their values in subsequent remission (YMRS ≤ 12). A total of 14 patients (33.3%) in acute mania and 30 patients (71.4%) in subsequent remission met the Taiwanese criteria for hyperinsulinaemia of ≥ 8.7 μIU/ml for men, and ≥ 11.3 μIU/ml for women. Multiple analyses were then undertaken, without correction, as the exploratory analyses. The measurement, by logistic regression, of the use of propranolol in remission (odds ratio [OR] = 10.04, 95% confidence interval [95% CI] = 1.03-97.96) and the increase in BMI (OR = 1.35, 95% CI = 1.01-1.80) were found to have independent associations with hyperinsulinaemia in subsequent remission. Our results suggest that medicated bipolar manic patients are vulnerable to hyperinsulinaemia in early remission, particularly those gaining bodyweight or those using β-adrenoceptor antagonist (beta-blockers), irrespective of the types of mood stabilizers or antipsychotics used.

KW - Beta-blocker

KW - Bipolar I disorder in Taiwan

KW - Bodyweight gain

KW - Hyperinsulinaemia

KW - Insulin resistance

KW - Manic episode

UR - http://www.scopus.com/inward/record.url?scp=34249303743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249303743&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2007.03.003

DO - 10.1016/j.pnpbp.2007.03.003

M3 - Article

C2 - 17449158

AN - SCOPUS:34249303743

VL - 31

SP - 1038

EP - 1043

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 5

ER -